CA
NZ
UK
AU
IND
US
Ginkgo Bioworks (NYSE:DNA) shares are sinking today after TD Cowen downgraded the stock to Hold from Buy, cutting its price target to $9 from $12, citing uncertainty around the company's near-term growth drivers. The downgrade follows second-quarter results in which revenue fell 19% year-over-year …
Hims & Hers Health (NYSE:HIMS) shares are climbing further today as investors position ahead of the company's second-quarter earnings report, due after market close on August 10. The move builds on last week's rebound from a selloff tied to a Federal Trade Commission-related issue. …
Humana (NYSE:HUM) is trading higher today, building on momentum from its second-quarter earnings report released on July 29. The health insurer posted revenue of $40.89 billion, edging past the $40.98 billion estimate, while adjusted earnings per share of $7.61 came in well ahead of …
Personalis (NASDAQ:PSNL) shares are climbing further today as investors continue to digest a strong second-quarter report alongside the pending Tempus AI merger. Clinical test volume surged 199% year-over-year to 10,384 tests, while Q2 revenue grew 30% to $22.4 million. The stock's rally reflects continued …
If you're watching Agilon Health (NYSE:AGL) today, the stock is rebounding sharply, up nearly 11% intraday as it claws back part of the nearly 20% post-earnings selloff seen after Wednesday's second-quarter report. Q2 results showed a return to profitability, with net income of $18 …
Alignment Healthcare (NASDAQ:ALHC) shares are stabilizing today, up nearly 7% after a brutal multi-week selloff triggered by a whistleblower lawsuit alleging the company misclassified $8-10 million in operating expenses to inflate adjusted EBITDA, prompting multiple law firms to investigate potential securities class actions. Despite …
Surge in Digital Medical Platform Shares
This figure represents a notable increase from $13.9 million reported at the end of March. The growth in cash is primarily attributed to proceeds from a private placement and expected reimbursement from research collaborations. These funds not only bolster the company’s financial standing but …
NRX Pharmaceuticals (NASDAQ: NRXP) received FDA clarification that a major packaging deficiency concerning the twist‑off cap of its preservative‑free ketamine vial has been addressed, allowing the agency to immediately re‑initiate the Abbreviated New Drug Application (ANDA) review. The company supplied data showing that the …
This improvement is largely due to a substantial cut in operating expenses, which plummeted 98% to $62,000, following the winding down of clinical trials. Revenue for the quarter fell 24% to $621,000, primarily affected by slumping reagent sales and reduced service revenue stemming from …
Please wait processing your request...